Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure

Table 5 Baseline characteristics of patients whose baseline potassium level ≤ 3.8 mEq/L stratified based on the presence or absence of hypernatremia

	With hypernatremia (n = 10)	Without hypernatremia (n = 19)	p value
Serum sodium, mEq/L	144 ± 2	142 ± 2	0.080
ACEI/ARB, %	60	53	0.717
MRA, %	30	26	0.840
Loop diuretics, %	50	58	0.697
FENa, %	2.3 ± 2.1	3.7 ± 5.6	0.624
FEUN, %	42.0 ± 8.5	39.8 ± 9.0	0.665
FEK, %	12.6 ± 7.2	14.7 ± 10.1	0.684
TTKG	3.6 ± 1.8	4.0 ± 1.6	0.677
PRA, ng/mL/h	0.5 ± 0.4	3.5 ± 5.9	0.241
PAC, pg/mL	57.3 ± 31.0	80.1 ± 53.6	0.353
PAC/PRA	186 ± 211	114 ± 112	0.353
Systolic blood pressure, mmHg	157 ± 22	139 ± 22	0.050
Diastolic blood pressure, mmHg	97 ± 20	75 ± 17	0.004

ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, MRA mineralocorticoid receptor antagonist, FENa fractional excretion of sodium, FEUN fractional excretion of urea nitrogen, FEK fractional excretion of potassium, TTKG trans-tubular K gradient, PRA plasma renin activity, PAC plasma aldosterone concentration, PAC/PRA, ratio of plasma aldosterone concentration to plasma renin activity

ISSN: 1471-2261